10-Q: Surrozen Secures Key Funding, Shifts Focus to Ophthalmology

Surrozen, Inc. reported a net income of $39.7 million for Q2 2025, driven by non-cash gains from warrant and tranche liability fair value adjustments, and secured significant funding for its ophthalmology pipeline.

Summary

• Reported a net income of $39.7 million for the three months ended June 30, 2025, a significant improvement from a net loss of $25.3 million in the prior year period.
• Achieved a net income of $12.8 million for the six months ended June 30, 2025, compared to a net loss of $34.1 million for the same period in 2024.
• The net income was primarily driven by non-cash gains of $47.6 million and $104.6 million on changes in fair value of tranche liability and warrant liabilities for the three and six months ended June 30, 2025, respectively.
• Cash and cash equivalents increased significantly to $90.4 million as of June 30, 2025, up from $34.6 million at December 31, 2024, largely due to a private placement.
• Successfully closed the first tranche of a $175.0 million two-tranche private placement (2025 PIPE) in March 2025, generating approximately $71.2 million in net proceeds.
• Discontinued the clinical development of SZN-043 in severe alcohol associated hepatitis in Q1 2025 due to insufficient early signal of clinical benefit.
• Nominated SZN-8141 and SZN-8143 as development candidates for retinal diseases in Q3 2024, with an Investigational New Drug (IND) application for SZN-8141 expected in 2026.
• Recognized $1.0 million and $2.0 million in research service revenue from a related party (TCGFB, Inc.) for the three and six months ended June 30, 2025, respectively.
• Boehringer Ingelheim International GmbH (BI) decided to move forward with the development of SZN-413 in September 2024, triggering a $10.0 million milestone payment.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a significant increase in cash reserves from a successful private placement, a swing to net income (albeit largely non-cash), and strategic pipeline advancements in ophthalmology. However, this is tempered by continued operational losses, the inherent risks of clinical development, and the reliance on future capital raises.

Positives

• Achieved a net income of $39.7 million for Q2 2025 and $12.8 million for the first six months of 2025, a substantial improvement over prior year losses.
• Significantly increased cash and cash equivalents to $90.4 million, providing a stronger financial runway.
• Successfully completed the first tranche of the 2025 PIPE, securing $71.2 million in net proceeds to fund ophthalmology programs.
• Received a $10.0 million milestone payment from Boehringer Ingelheim for the continued development of SZN-413.
• Strategic focus on ophthalmology programs (SZN-8141, SZN-8143, SZN-113) following the discontinuation of SZN-043, streamlining the pipeline.
• Entered into a strategic research collaboration with TCGFB, Inc., generating new research service revenue.

Negatives

• Incurred operating losses of $9.0 million for Q2 2025 and $18.6 million for the first six months of 2025, indicating continued cash burn from core operations.
• Experienced a non-cash loss of $71.1 million upon the execution of the 2025 PIPE due to the fair value of tranche liability exceeding committed proceeds.
• Incurred a $2.1 million non-cash loss from the amendment and cancellation of 2024 PIPE Warrants, including the cancellation of Series C and D warrants due to SZN-043 discontinuation.
• Research and development expenses increased by 19% for the six months ended June 30, 2025, reflecting higher manufacturing costs and consulting fees.
• Used $15.4 million in cash for operating activities during the first six months of 2025, an increase from $14.4 million in the prior year period.

Risks

• Continued significant operating losses are expected for the foreseeable future, and profitability may never be achieved or maintained.
• Substantial additional funds will be needed to advance product candidates, and there is no guarantee of sufficient future funding.
• None of the product candidates have received regulatory approval, and successful commercialization depends on obtaining such approvals.
• Product candidates may demonstrate undesirable safety or tolerability side effects, which could compromise marketability or regulatory approval.
• Future equity or debt issuances may have dilutive or adverse effects on existing stockholders.
• Reliance on third parties to conduct preclinical studies and clinical trials may lead to unsatisfactory performance or delays.
• Clinical development activities could be delayed or adversely affected by various factors, including patient enrollment difficulties.
• The manufacturing of product candidates is complex, and difficulties in production could delay or halt supply for trials or commercial sale.
• Intense competition from other pharmaceutical and biotechnology companies could adversely affect the ability to commercialize product candidates.
• Inability to maintain proper and effective internal controls over financial reporting could adversely affect financial reporting accuracy and stock price.
• International operations expose the company to business, political, operational, and financial risks, including tariffs and trade barriers.
• Significant risk of product liability, and insufficient insurance coverage could have a material adverse effect.
• Employees, principal investigators, consultants, and commercial collaborators may engage in misconduct or improper activities.
• Failure to comply with health and data protection laws and regulations could lead to enforcement actions, litigation, or adverse publicity.
• Dependence on sophisticated information technology systems and data processing makes the company vulnerable to security or data privacy breaches.
• Inadequate funding for regulatory agencies could hinder their ability to review and approve new product candidates in a timely manner.
• The stock price may be volatile, and purchasers of common stock could incur substantial losses.
• A few stockholders, including a director, control a large number of voting rights, potentially affecting corporate decisions.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Claims for indemnification by directors and officers may reduce available funds to satisfy third-party claims.
• As an emerging growth company and smaller reporting company, certain exemptions from disclosure requirements may make securities less attractive to investors.

Future Outlook

Management believes existing cash and cash equivalents are sufficient to fund operations for at least the next 12 months from the filing date. The company expects to file an Investigational New Drug (IND) application and commence clinical studies for SZN-8141 in 2026. The second tranche of the 2025 PIPE, expected to provide $98.6 million, is contingent upon FDA clearance of the SZN-8141 IND application by October 31, 2026, and is expected to fund operations through initial Phase 1 safety, tolerability, and efficacy studies for SZN-8141 and SZN-8143. The company anticipates needing to raise additional capital in the long-term to continue executing its business plan and advance product candidates through clinical development and regulatory submissions.

Management Comments

• Management believes that the existing cash and cash equivalents are sufficient for the company to continue operating activities for at least the next 12 months from the date of issuance of its unaudited condensed consolidated financial statements.
• The company expects operating expenses to continue to be significant in connection with its ongoing pre-clinical studies and preparation for clinical studies, and anticipates the need to raise additional capital to continue to execute its long-range business plan.

Industry Context

Surrozen operates in the highly competitive and rapidly advancing biotechnology industry, specializing in modulating the Wnt pathway for tissue repair. Its strategic shift to focus on ophthalmology indications, particularly retinal diseases, positions it within a segment with high unmet medical needs and significant market potential. The development of multi-specific antibody-based therapeutics like SZN-8141 and SZN-8143 aims to differentiate from existing anti-VEGF monotherapies, aligning with a trend towards more comprehensive treatment approaches in complex diseases. The discontinuation of SZN-043 reflects the high-risk nature of drug development and the need for companies to strategically allocate resources to programs with the most promising early signals.

Comparison to Industry Standards

• The filing states that the current standard of care for diabetic retinopathy (including DME), retinal vein occlusion, and wet AMD is intravitreal administration of anti-VEGF monotherapies. Surrozen's SZN-8141 and SZN-8143 aim to provide benefits over these single agents by combining Frizzled 4 (Fzd4) agonism with VEGF antagonism, and additionally IL-6 antagonism for SZN-8143.
• Fzd4 monotherapy has demonstrated proof of concept in DME in clinical trials, suggesting a validated mechanism for Surrozen's Fzd4-targeting candidates.
• No specific comparable companies, projects, or detailed competitive results are provided within the filing for direct quantitative comparison.

Legal Proceedings

• Not currently a party to or aware of any proceedings that are believed to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• Collaboration and License Agreement with Boehringer Ingelheim International GmbH (BI): BI is a significant collaborator, and a $10.0 million milestone payment was triggered in September 2024.
• Strategic Research Collaboration with TCGFB, Inc.: TCGFB was founded and is controlled by entities affiliated with The Column Group, a significant stockholder. The company provides antibody discovery services for a fixed monthly fee and received a warrant for TCGFB common stock.
• 2024 Private Placement: Certain members of management participated in the 2024 PIPE, purchasing common stock and warrants.
• Sublease Agreement with Nura Bio, Inc.: Nura Bio is a related party as a member of Surrozen's board of directors also serves as chairman of Nura Bio's board and Managing Partner of The Column Group, a significant stockholder of Nura Bio. Surrozen subleases office and laboratory space to Nura Bio.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings and warrant exercises, but also potential for increased value from successful pipeline development and extended cash runway. Stock price volatility is a significant risk.
• Employees: Stock-based compensation plans are in place. The company's ability to attract and retain qualified personnel is critical for success.
• Customers/Collaborators: Continued collaboration with BI and TCGFB indicates ongoing partnerships. Discontinuation of SZN-043 may impact certain research relationships.
• Suppliers/Creditors: Reliance on third-party manufacturers and CROs for preclinical and clinical development, which could be impacted by supply chain disruptions or performance issues.
• Patients: Development of new drug candidates in ophthalmology aims to address unmet medical needs, offering potential future treatment options.

Next Steps

• File an Investigational New Drug (IND) application for SZN-8141 in 2026.
• Commence clinical studies for SZN-8141 in 2026.
• Potential closing of the second tranche of the 2025 PIPE, contingent on SZN-8141 IND clearance by October 31, 2026.
• Continue ongoing preclinical studies and prepare for clinical studies for other ophthalmology programs (SZN-8143, SZN-113).
• Continue antibody discovery services for TCGFB, Inc. for up to two years.

Key Dates

Recommendation

The company has significantly bolstered its cash position through a successful private placement, providing a runway for at least the next 12 months and potentially much longer with the second tranche. This funding is crucial for advancing its focused ophthalmology pipeline, which includes promising candidates like SZN-8141 and SZN-8143. While the reported net income is largely due to non-cash accounting adjustments and operational cash burn continues, the substantial capital infusion and strategic pipeline focus on high-potential areas like retinal diseases represent a strong positive signal for long-term growth. The discontinuation of SZN-043, while a setback, allows for better resource allocation. For risk-tolerant investors with a long-term horizon, the current valuation may present a compelling entry point given the strengthened financial position and clear development path.

Keywords

Biotechnology, Wnt pathway, Ophthalmology, Retinal diseases, Drug development, Clinical trials, SEC filing, 10-Q, Biopharmaceutical, SZN-8141, SZN-8143, SZN-113, SZN-413, Private placement, Warrants, Tranche liability